Agios Pharmaceuticals (AGIO) Stock
Biotech developing metabolism therapies for cancer and rare diseases. Here's the price, business snapshot, and what's worth knowing about Agios Pharmaceuticals in July 2026.
Agios Pharmaceuticals (AGIO) is a US biotechnology company focused on therapies that target cellular metabolism, with programmes in oncology and rare genetic diseases. Investors should know this is a pipeline-driven business: value depends heavily on clinical-trial results, regulatory decisions and any commercial uptake of approved medicines. The company has product revenues alongside R&D spending and may pursue partnerships and licensing to broaden reach. With a market capitalisation near $2.52 billion, Agios sits in the mid-cap biotech range — offering meaningful upside if development milestones succeed, but also notable downside if trials fail or approvals are delayed. Expect volatility, ongoing cash burn while R&D continues, and periodic binary events that can move the share price. This summary is educational, not personalised investment advice; consider your risk tolerance and time horizon and consult a financial adviser before acting.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying AGIOS Pharmaceuticals stock with a target price of $48.5, indicating potential growth.
Financial Health
Agios Pharmaceuticals is doing well with high profits and cash flow, indicating strong financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring AGIO
UK-US Pharma Trade Deal | Tariff-Free Market Access
A new trade deal eliminates tariffs on pharmaceuticals between the UK and the US, strengthening transatlantic trade. This creates a powerful tailwind for pharmaceutical companies in both countries, potentially boosting exports, innovation, and profitability.
Published: 2 December 2025
Explore BasketSanofi Dupixent Success Overview | Pharma Investment
Sanofi's recent profit surge, driven by its blockbuster drug Dupixent, highlights a powerful investment theme. This idea focuses on innovative pharmaceutical companies with high-growth drugs and the broader ecosystem that supports their success.
Published: 24 October 2025
Explore BasketPharma M&A Targets (Metabolic Disease Biotechs)
Novo Nordisk's $5.2 billion acquisition of Akero Therapeutics highlights a strategic push into the MASH treatment market. This deal could trigger a wave of similar acquisitions, boosting the value of other biotech firms with promising drugs for metabolic diseases.
Published: 10 October 2025
Explore BasketHematology Stocks | BTK Inhibitor FDA Breakthrough
Following the FDA's approval of Sanofi's Wayrilz, the first BTK inhibitor for a rare blood disorder, a new investment opportunity has emerged. This theme focuses on innovative pharmaceutical companies developing next-generation treatments for rare hematological diseases, a market poised for significant growth.
Published: 30 August 2025
Explore BasketOrphan Drug Moats: Leaders In Rare Disease
The FDA's rejection of PTC Therapeutics' drug for a rare genetic disorder has delayed a new treatment option and created a significant setback for the company. This regulatory decision strengthens the competitive position of companies with already-approved therapies for rare diseases, highlighting the value of a proven drug portfolio.
Published: 20 August 2025
Explore BasketPioneers In Rare Disease Therapy
The FDA's approval of PTC Therapeutics' drug for the rare disorder PKU marks a significant advancement in metabolic disease treatment. This event creates an investment opportunity by highlighting the growth potential of other biopharmaceutical companies specializing in therapies for rare genetic conditions.
Published: 29 July 2025
Explore BasketPharma's Next Big Deal
This carefully curated group of stocks features promising biotech companies with valuable drug pipelines. These smaller firms could become the next targets for lucrative partnerships or acquisitions by pharmaceutical giants, similar to Glenmark's recent $2 billion deal with AbbVie.
Published: 11 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical trial readouts and approvals can rapidly change valuation, offering potential upside while also creating volatility from binary outcomes.
Innovative Science
A focus on metabolic targets differentiates Agios, but long and costly R&D means results are uncertain and timelines can shift.
Commercial Upside
Approved products and partnerships can provide revenue and validation, though market uptake and competition may limit returns.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
